UniQure surges 80% as FDA reverses stance on gene therapy filing

The FDA's reversal on uniQure's Huntington's disease gene therapy clears a path to accelerated approval, handing the biotech a second chance at a filing it was denied just three months ago.

The U.S. Food and Drug Administration told uniQure that three-year data from a Phase 1/2 study of AMT-130 would be acceptable as the primary basis for an accelerated approval application in Huntington's disease, the company said June 17. The decision marks a sharp reversal from March, when the agency rejected the same data and demanded a placebo-controlled trial before any submission.

"The FDA's willingness to accept the three-year analysis reflects an appreciation of the challenges in rare disease following the overhaul of its leadership," Guggenheim Securities analysts said in a note. Former FDA commissioners Marty Makary and Vinay Prasad, who held top positions when uniQure first sought the accelerated path, have since left the agency.

UniQure plans to submit the Biologics License Application in the third quarter of 2026. The company's shares surged 80% to $48.51 in premarket trading on the news. The biotech still needs to reach agreement with the FDA on a confirmatory study design, with the agency seeking alignment on using a concurrent control for standard-of-care therapy rather than the previously requested sham procedure.

What the data show

AMT-130 is a gene therapy designed to slow Huntington's disease progression by delivering a gene-silencing mechanism directly to brain cells. In the Phase 1/2 trial, uniQure reported that the therapy slowed disease progression by 75% compared with an external control database of untreated patients, according to CNBC. There are currently no FDA-approved treatments that slow or prevent Huntington's, a fatal genetic disorder that affects about 40,000 Americans, with an estimated 1,383 new privately insured diagnoses annually.

The company's approach uses an adeno-associated virus vector to deliver a microRNA targeting the huntingtin gene, the root cause of the disease. This mechanism differs from standard symptomatic treatments, which only manage chorea and other motor symptoms without addressing the underlying neurodegeneration.

Cash runway and dilution risk

UniQure remains lossmaking with modest revenue and relies heavily on AMT-130 as its lead asset. The company recently increased its authorized share capital after shareholders approved changes to its Dutch articles of association, keeping dilution risk on the table as it prepares for a potential launch. Gene therapies for rare diseases typically cost between $2 million and $4.5 million per dose in the U.S., and analysts expect AMT-130 to price near the high end of that range given the absence of disease-modifying alternatives.

The confirmatory study requirement adds another layer of execution risk. UniQure said it is "committed to conducting the confirmatory study without delay," though the FDA may require full enrollment before granting accelerated approval. The company's cash position and the timeline for that study will determine whether it can reach the market without additional financing.

For investors, the FDA's U-turn resets the risk-reward calculus. If approved, AMT-130 would be the first disease-modifying therapy for Huntington's, addressing a total addressable market of roughly 40,000 U.S. patients. But the stock's 80% surge already prices in a high probability of approval, leaving limited upside if the confirmatory study design proves more burdensome than expected. Rezolute and Regenxbio shares also ticked higher on the news, reflecting hopes that the agency's flexibility on rare disease evidence extends beyond uniQure.

This article is for informational purposes only and does not constitute investment advice.